Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Elevation brings Synaffix on board in HER3
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
ASH 2024 – Arcellx is happy to share in Car-T
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
